Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Average Rating of “Hold” from Analysts

Hyperion DeFi, Inc. (NASDAQ:HYPD) has received a consensus rating of “Hold” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $4.5833.

Several research analysts have weighed in on HYPD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a report on Monday, December 29th. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Cantor Fitzgerald began coverage on shares of Hyperion DeFi in a report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target on the stock. Finally, Chardan Capital set a $7.75 price target on shares of Hyperion DeFi and gave the stock a “buy” rating in a research note on Wednesday, December 24th.

Insider Transactions at Hyperion DeFi

In other news, CFO David R. Knox acquired 27,950 shares of Hyperion DeFi stock in a transaction on Wednesday, December 31st. The shares were acquired at an average price of $3.59 per share, with a total value of $100,340.50. Following the purchase, the chief financial officer directly owned 327,950 shares in the company, valued at $1,177,340.50. The trade was a 9.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Happy David Walters bought 61,930 shares of the stock in a transaction dated Wednesday, December 17th. The shares were purchased at an average price of $3.02 per share, with a total value of $187,028.60. Following the completion of the transaction, the director directly owned 111,930 shares in the company, valued at approximately $338,028.60. The trade was a 123.86% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 189,204 shares of company stock valued at $611,467 in the last ninety days. Corporate insiders own 10.86% of the company’s stock.

Hedge Funds Weigh In On Hyperion DeFi

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in shares of Hyperion DeFi during the fourth quarter worth $663,000. Price T Rowe Associates Inc. MD bought a new stake in Hyperion DeFi during the 4th quarter valued at about $73,000. State Street Corp purchased a new stake in Hyperion DeFi in the 4th quarter valued at about $92,000. Jane Street Group LLC purchased a new stake in Hyperion DeFi in the 4th quarter valued at about $493,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in Hyperion DeFi in the 4th quarter worth about $221,000. 25.84% of the stock is owned by hedge funds and other institutional investors.

Hyperion DeFi Price Performance

Shares of Hyperion DeFi stock opened at $3.52 on Thursday. The company has a market capitalization of $28.76 million, a price-to-earnings ratio of -0.87 and a beta of 2.69. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11. The stock’s 50-day simple moving average is $3.57 and its 200-day simple moving average is $5.88. Hyperion DeFi has a 52 week low of $0.85 and a 52 week high of $17.18.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.